Pascal Soriot: Difference between revisions

The neutral encyclopedia of notable people
Content engine: create biography for Pascal Soriot (2515 words)
 
Content engine: create biography for Pascal Soriot (2279 words) [update]
 
Line 7: Line 7:
| nationality      = French, Australian
| nationality      = French, Australian
| occupation      = Businessman
| occupation      = Businessman
| known_for        = CEO of [[AstraZeneca]]
| title            = CEO, AstraZeneca
| title            = Chief Executive Officer, AstraZeneca
| years_active    = 1982–present
| education        = [[École nationale vétérinaire d'Alfort]]<br/>[[HEC Paris]]
| education        = [[École nationale vétérinaire d'Alfort]]<br/>[[HEC Paris]]
| years_active    = 1982–present
| children        = 2
| children        = 2
| honours          = [[Knight Bachelor]] (2022)
| honours          = [[Knight Bachelor]]
}}
}}


'''Sir Pascal Claude Roland Soriot''' (born 23 May 1959) is a French-born Australian businessman who has served as the chief executive officer of [[AstraZeneca]], the British-Swedish multinational pharmaceutical and biotechnology company, since 2012. Over the course of more than a decade at the helm, Soriot has overseen a significant transformation of the company, steering it from a period of declining revenues and patent expiries toward a focus on oncology and other growth areas. His leadership during the [[COVID-19 pandemic]], when AstraZeneca partnered with the [[University of Oxford]] to develop and distribute one of the world's most widely used vaccines, brought him considerable public prominence. Prior to joining AstraZeneca, Soriot held senior positions at [[Roche]] and spent several years at [[Sanofi]] (then Aventis), building a career that spans more than four decades in the global pharmaceutical industry. He was awarded a [[Knight Bachelor|British knighthood]] in 2022 for services to UK life sciences and his leadership in the global response to the COVID-19 pandemic.<ref name="knighthood">{{cite web |title=AstraZeneca's Pascal Soriot awarded British knighthood for services to UK life sciences and leadership of global response to COVID pandemic |url=https://www.astrazeneca.com/media-centre/press-releases/2022/astrazenecas-pascal-soriot-awarded-british-knighthood-services-uk-life-sciences-leadership-global-response-covid-pandemic.html |publisher=AstraZeneca |date=2022 |access-date=2026-02-24}}</ref>
'''Sir Pascal Claude Roland Soriot''' (born 23 May 1959) is a French-born Australian businessman who has served as chief executive officer of [[AstraZeneca]], the British-Swedish multinational pharmaceutical and biotechnology company, since 2012. Appointed at a time when the company faced expiring patents on key drugs and a thinning development pipeline, Soriot oversaw a strategic transformation that repositioned AstraZeneca as a major force in [[oncology]] and other therapeutic areas. His tenure has been marked by large-scale investment in research and development, significant revenue growth, and a prominent role during the [[COVID-19 pandemic]], when AstraZeneca partnered with the [[University of Oxford]] to develop and distribute one of the world's most widely used vaccines. Before joining AstraZeneca, Soriot held senior positions at [[Roche]] and spent more than two decades at various pharmaceutical firms. He was awarded a [[Knight Bachelor|British knighthood]] in the 2022 New Year Honours for services to the United Kingdom's life sciences sector and for his leadership during the global response to the COVID-19 pandemic.<ref name="knighthood">{{cite web |title=AstraZeneca's Pascal Soriot awarded British Knighthood for services to UK life sciences and leadership of global response to the COVID pandemic |url=https://www.astrazeneca.com/media-centre/press-releases/2022/astrazenecas-pascal-soriot-awarded-british-knighthood-services-uk-life-sciences-leadership-global-response-covid-pandemic.html |publisher=AstraZeneca |date=2022 |access-date=2026-02-24}}</ref> In recent years, Soriot has been an outspoken advocate for European competitiveness in the pharmaceutical sector, warning that the continent risks falling behind the United States and China in life sciences innovation.<ref name="lemonde">{{cite news |date=2025-12-18 |title=AstraZeneca CEO Pascal Soriot: 'The pharmaceutical industry in Europe will be reduced to a shadow of itself within 15 years' |url=https://www.lemonde.fr/en/economy/article/2025/12/18/astrazeneca-ceo-pascal-soriot-the-pharmaceutical-industry-in-europe-will-be-reduced-to-a-shadow-of-itself-within-15-years_6748620_19.html |work=Le Monde |access-date=2026-02-24}}</ref>


== Early Life ==
== Early Life ==


Pascal Claude Roland Soriot was born on 23 May 1959 in France. Details regarding his family background and childhood have not been extensively documented in publicly available sources. Soriot would go on to pursue a scientific and business education that prepared him for a career in the pharmaceutical sector, eventually settling in Australia, where he acquired citizenship, making him a dual French-Australian national.
Pascal Claude Roland Soriot was born on 23 May 1959 in France. Details regarding his family background and upbringing have not been extensively documented in public sources. He later obtained Australian citizenship, and is frequently described in corporate and media profiles as French-born Australian.<ref name="lemonde" /><ref name="guardian">{{cite news |last= |first= |date=2012-08-28 |title=AstraZeneca names new chief executive Pascal Soriot |url=https://www.theguardian.com/business/2012/aug/28/astrazeneca-new-chief-executive-pascal-soriot |work=The Guardian |access-date=2026-02-24}}</ref>


== Education ==
== Education ==


Soriot studied veterinary science at the [[École nationale vétérinaire d'Alfort]], one of France's oldest and most prestigious veterinary schools located near Paris. He subsequently attended [[HEC Paris]], the elite French business school, where he obtained additional qualifications in business and management. This combination of scientific training and business education provided a foundation for his career in the pharmaceutical industry, blending an understanding of biological sciences with strategic and commercial expertise.<ref name="roche_cv">{{cite web |title=Pascal Soriot CV |url=http://www.roche.com/cv_soriot.pdf |publisher=Roche |access-date=2026-02-24}}</ref>
Soriot studied at the [[École nationale vétérinaire d'Alfort]], one of France's leading veterinary schools, where he received training in veterinary science. He subsequently attended [[HEC Paris]], the prestigious French business school, where he completed a programme in business administration.<ref name="roche_cv">{{cite web |title=CV Pascal Soriot |url=http://www.roche.com/cv_soriot.pdf |publisher=Roche |date= |access-date=2026-02-24}}</ref> This combination of scientific and business education formed the foundation for his career in the pharmaceutical industry.


== Career ==
== Career ==


=== Early Career and Sanofi ===
=== Early Career and Pharmaceutical Industry Beginnings ===


Soriot began his professional career in the pharmaceutical industry in 1982.<ref name="roche_cv"/> He spent a number of years in various roles across the sector, including a significant period at the French pharmaceutical company that would eventually become [[Sanofi]]. During the complex merger process between Sanofi and Aventis in 2004, which resulted in the creation of one of the world's largest pharmaceutical companies, Soriot was among the senior executives involved in the combined organisation's operations.<ref>{{cite web |title=SEC Filing regarding Sanofi-Aventis merger |url=https://www.sec.gov/Archives/edgar/data/1121404/000095012304015148/y04039asv8.htm |publisher=U.S. Securities and Exchange Commission |date=2004 |access-date=2026-02-24}}</ref> His experience at Sanofi-Aventis exposed him to the challenges and opportunities of operating a major global pharmaceutical enterprise, including navigating regulatory environments across multiple continents and managing large-scale commercial operations.
Soriot began his professional career in the pharmaceutical sector in 1982.<ref name="roche_cv" /> Over the following decades, he held positions at several major pharmaceutical companies. His early career included roles at firms operating across the global pharmaceutical landscape, during which he gained experience in commercial operations and general management across multiple geographic markets.


=== Roche ===
=== Roche ===


After his tenure at Sanofi-Aventis, Soriot moved to [[Roche]], the Swiss pharmaceutical and diagnostics company, where he rose to a senior leadership position. At Roche, he served as a member of the company's executive committee, taking on the role of chief operating officer of the pharmaceuticals division.<ref name="roche_profile">{{cite web |title=Executive Committee – Pascal Soriot |url=http://www.roche.com/about_roche/management/executive_committee/executive_commitee-pascal-soriot.htm |publisher=Roche |access-date=2026-02-24}}</ref><ref name="bloomberg_profile">{{cite web |title=Pascal Soriot Profile |url=https://www.bloomberg.com/research/stocks/people/person.asp?personId=11538206&ticker=RO:SW |publisher=Bloomberg |access-date=2026-02-24}}</ref> Roche's pharmaceuticals division was among the world's largest, with particular strength in oncology and a growing biologics portfolio. Soriot's role at Roche gave him direct experience in overseeing a portfolio of innovative medicines, managing large clinical development programmes, and leading commercial strategy in competitive therapeutic areas. His work at Roche also provided him with deep exposure to the oncology market, a field that would later become central to his strategy at AstraZeneca.
Before joining AstraZeneca, Soriot served as chief operating officer of the pharmaceuticals division at [[Roche]], the Swiss multinational healthcare company.<ref name="roche_profile">{{cite web |title=Executive Committee – Pascal Soriot |url=http://www.roche.com/about_roche/management/executive_committee/executive_commitee-pascal-soriot.htm |publisher=Roche |date= |access-date=2026-02-24}}</ref> At Roche, he was a member of the corporate executive committee and was responsible for overseeing the company's global pharmaceutical commercial operations. His tenure at Roche established his reputation as a senior pharmaceutical industry executive with deep expertise in drug commercialisation and operations management.<ref name="bloomberg_roche">{{cite web |title=Pascal Soriot – Executive Profile |url=https://www.bloomberg.com/research/stocks/people/person.asp?personId=11538206&ticker=RO:SW |publisher=Bloomberg |date= |access-date=2026-02-24}}</ref><ref name="roche_former">{{cite web |title=Pascal Soriot – Former Executive Committee Member |url=https://www.roche.com/about/governance/ec-bod-former/pascal-soriot |publisher=Roche |date= |access-date=2026-02-24}}</ref>
 
=== Appointment as AstraZeneca CEO ===
 
On 28 August 2012, AstraZeneca announced that Soriot would become its new chief executive officer, succeeding David Brennan.<ref name="bloomberg_appt">{{cite news |date=2012-08-28 |title=AstraZeneca Names Roche's Pascal Soriot as CEO |url=https://www.bloomberg.com/news/2012-08-28/astrazeneca-names-roche-s-pascal-soriot-as-ceo.html |work=Bloomberg |access-date=2026-02-24}}</ref> The appointment was widely reported in the financial press, as AstraZeneca was at the time facing substantial challenges. The company's portfolio included several blockbuster drugs that were nearing the end of their patent protection, raising concerns about future revenue declines. Its research and development pipeline was considered thin relative to its peers, and investor confidence had waned.<ref name="nyt">{{cite news |date=2012-08-29 |title=AstraZeneca's Next C.E.O. Is Pascal Soriot of Roche |url=https://www.nytimes.com/2012/08/29/business/astrazenecas-next-ceo-is-pascal-soriot-of-roche.html |work=The New York Times |access-date=2026-02-24}}</ref><ref name="guardian" />


=== Appointment as CEO of AstraZeneca ===
The ''Daily Telegraph'' reported that Soriot's background at Roche, where he had overseen the commercial operations of some of the industry's leading cancer drugs, made him a strong candidate to lead AstraZeneca's turnaround.<ref name="telegraph_appt">{{cite news |date=2012-08-28 |title=AstraZeneca appoints Roche's Pascal Soriot as new chief |url=https://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/9504462/AstraZeneca-appoints-Roches-Pascal-Soriot-as-new-chief.html |work=The Daily Telegraph |access-date=2026-02-24}}</ref>


On 28 August 2012, AstraZeneca announced the appointment of Pascal Soriot as its new chief executive officer, effective later that year.<ref name="nyt_appointment">{{cite news |last= |first= |date=2012-08-29 |title=AstraZeneca's Next C.E.O. Is Pascal Soriot of Roche |url=https://www.nytimes.com/2012/08/29/business/astrazenecas-next-ceo-is-pascal-soriot-of-roche.html |work=The New York Times |access-date=2026-02-24}}</ref><ref name="guardian_appointment">{{cite news |last= |first= |date=2012-08-28 |title=AstraZeneca appoints new chief executive Pascal Soriot |url=https://www.theguardian.com/business/2012/aug/28/astrazeneca-new-chief-executive-pascal-soriot |work=The Guardian |access-date=2026-02-24}}</ref> Soriot was recruited from Roche to lead the British-Swedish pharmaceutical company at a time of considerable uncertainty. AstraZeneca was facing the expiration of patents on several of its major products, a situation commonly referred to in the industry as a "patent cliff," which was expected to lead to significant revenue declines as generic competitors entered the market.<ref name="telegraph_appointment">{{cite news |last= |first= |date=2012 |title=AstraZeneca appoints Roche's Pascal Soriot as new chief |url=https://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/9504462/AstraZeneca-appoints-Roches-Pascal-Soriot-as-new-chief.html |work=The Daily Telegraph |access-date=2026-02-24}}</ref><ref name="bloomberg_appointment">{{cite news |last= |first= |date=2012-08-28 |title=AstraZeneca Names Roche's Pascal Soriot as CEO |url=https://www.bloomberg.com/news/2012-08-28/astrazeneca-names-roche-s-pascal-soriot-as-ceo.html |work=Bloomberg |access-date=2026-02-24}}</ref>
=== Transformation of AstraZeneca ===


The company's research and development pipeline at the time was widely seen as insufficient to replace the revenue from expiring blockbusters. Soriot was tasked with revitalising the company's drug development efforts and restoring growth. He moved quickly to refocus AstraZeneca's strategy around three core therapeutic areas: oncology, cardiovascular and metabolic diseases, and respiratory and immunology. He also emphasised the importance of science-driven innovation and invested heavily in rebuilding the pipeline through both internal research and external acquisitions and partnerships.
Upon taking charge, Soriot embarked on a strategy centred on rebuilding the company's drug development pipeline through a combination of internal research investment and external acquisitions and partnerships. He placed a particular strategic emphasis on oncology, which became the cornerstone of AstraZeneca's growth strategy under his leadership. The company invested heavily in cancer treatment research and built a portfolio of oncology drugs that became a significant driver of revenue growth.<ref name="bloomberg_profile">{{cite news |date=2025-11-05 |title=AstraZeneca's CEO Is Willing to Compromise — When It's for Trump |url=https://www.bloomberg.com/news/features/2025-11-05/astrazeneca-ceo-pascal-soriot-on-the-trump-drug-price-deal-and-company-culture |work=Bloomberg |access-date=2026-02-24}}</ref>


=== Pfizer Takeover Bid (2014) ===
Bloomberg described Soriot as having turned AstraZeneca into "an oncology powerhouse" characterised by "a high-pressure culture and a deep relationship with the US."<ref name="bloomberg_profile" /> Le Monde noted in December 2025 that since taking over in 2012, Soriot had "transformed the British pharmaceutical company that once lagged" behind its competitors.<ref name="lemonde" />


In 2014, AstraZeneca became the target of a takeover approach from the American pharmaceutical giant [[Pfizer]], which made a series of increasingly higher bids for the company. The proposed acquisition attracted significant public and political attention, particularly in the United Kingdom, where concerns were raised about the potential impact on British pharmaceutical research and employment. Soriot led AstraZeneca's defence against the bid, arguing that the company's independent strategy would deliver greater long-term value to shareholders than Pfizer's offer.<ref name="standard_bid">{{cite news |last= |first= |date=2014 |title=AstraZeneca chief Pascal Soriot: I can carry on curing the company, says scientist in £63bn bid battle |url=https://www.standard.co.uk/business/markets/astrazeneca-chief-pascal-soriot-i-can-carry-on-curing-the-company-says-scientist-in-63bn-bid-battle-9383150.html |work=Evening Standard |access-date=2026-02-24}}</ref> The final Pfizer bid, reportedly worth approximately £63 billion, was ultimately rejected, and Pfizer withdrew. Soriot's successful defence of the company was seen as a defining moment in his tenure as CEO, placing his strategic vision for AstraZeneca's future under intense scrutiny and committing him to delivering on the promises he had made to shareholders during the bid process.
==== Pfizer Takeover Bid (2014) ====


=== Transformation and Oncology Focus ===
In 2014, AstraZeneca became the target of a major takeover bid from the American pharmaceutical company [[Pfizer]]. The ''Evening Standard'' reported on the bid battle, describing it as approximately £63 billion in value and quoting Soriot's defence of the company's independent strategy. Soriot argued that AstraZeneca could deliver greater value to shareholders by continuing to develop its pipeline as a standalone company rather than being absorbed into Pfizer.<ref name="standard">{{cite news |title=AstraZeneca chief Pascal Soriot: I can carry on curing the company, says scientist in £63bn bid battle |url=https://www.standard.co.uk/business/markets/astrazeneca-chief-pascal-soriot-i-can-carry-on-curing-the-company-says-scientist-in-63bn-bid-battle-9383150.html |work=Evening Standard |date=2014 |access-date=2026-02-24}}</ref> Pfizer's bid was ultimately unsuccessful, and AstraZeneca remained independent. The episode was considered a defining moment of Soriot's tenure, as the company's subsequent performance under his leadership vindicated his argument that AstraZeneca's pipeline would generate substantial value over time.


Under Soriot's leadership from 2012 onward, AstraZeneca underwent a significant strategic transformation, with oncology becoming the primary growth driver. The company pursued a series of acquisitions, licensing deals, and internal research investments to build what became one of the industry's most extensive oncology pipelines. Key products in areas such as lung cancer, breast cancer, and other tumour types emerged as major revenue contributors. By the mid-2020s, the results of this transformation were becoming increasingly evident. According to reporting from ''Le Monde'' in December 2025, Soriot "has transformed the British pharmaceutical company that once lagged" into a significantly stronger enterprise.<ref name="lemonde">{{cite news |last= |first= |date=2025-12-18 |title=AstraZeneca CEO Pascal Soriot: 'The pharmaceutical industry in Europe will be reduced to a shadow of itself within 15 years' |url=https://www.lemonde.fr/en/economy/article/2025/12/18/astrazeneca-ceo-pascal-soriot-the-pharmaceutical-industry-in-europe-will-be-reduced-to-a-shadow-of-itself-within-15-years_6748620_19.html |work=Le Monde |access-date=2026-02-24}}</ref>
==== Teva Pharmaceutical Approach (2017) ====


Bloomberg described AstraZeneca under Soriot as having been turned into "an oncology powerhouse with a high-pressure culture and a deep relationship with the US."<ref name="bloomberg_2025">{{cite news |last= |first= |date=2025-11-05 |title=AstraZeneca's CEO Is Willing to Compromise — When It's for Trump |url=https://www.bloomberg.com/news/features/2025-11-05/astrazeneca-ceo-pascal-soriot-on-the-trump-drug-price-deal-and-company-culture |work=Bloomberg |access-date=2026-02-24}}</ref> By early 2026, AstraZeneca had set ambitious growth targets, with the company aiming to have more than 25 blockbuster products by 2030 as part of a broader goal to reach $80 billion in revenue.<ref name="fierce_2026">{{cite news |last= |first= |date=2026-02 |title=AstraZeneca sets sights on 25+ blockbusters by 2030 to fuel $80B revenue ambition |url=https://www.fiercepharma.com/pharma/astrazeneca-sets-sights-25-blockbusters-2030-fuel-80b-revenue-ambition |work=Fierce Pharma |access-date=2026-02-24}}</ref> The company reported strong financial performance in 2025, with Soriot highlighting continued growth.<ref name="oncodaily">{{cite news |last= |first= |date=2026-02 |title=Strong 2025 Performance, Pascal Soriot Highlights Continued Growth – AstraZeneca |url=https://oncodaily.com/voices/pascal-soriot-454750 |work=Oncodaily |access-date=2026-02-24}}</ref>
In July 2017, reports emerged that Soriot had been approached to become the chief executive of [[Teva Pharmaceutical Industries]], the Israeli generic drug manufacturer. An Israeli newspaper reported that Soriot had agreed to take the position, prompting speculation about his potential departure from AstraZeneca.<ref name="endpts_teva">{{cite news |title=Israeli newspaper reports that AstraZeneca CEO Pascal Soriot has agreed to take the helm at Teva |url=https://endpts.com/israeli-newspaper-reports-that-astrazeneca-ceo-pascal-soriot-has-agreed-to-take-the-helm-at-teva/ |work=Endpoints News |date=2017 |access-date=2026-02-24}}</ref> Reuters also reported on the possibility of Soriot moving to Teva.<ref name="reuters_teva">{{cite news |title=Teva – AstraZeneca CEO |url=https://www.reuters.com/article/us-teva-pharm-ind-astrazeneca-ceo-idUSKBN19X2OB?il=0 |work=Reuters |date=2017 |access-date=2026-02-24}}</ref> However, the ''Daily Telegraph'' subsequently reported that Soriot appeared set to remain at AstraZeneca, and he ultimately did not take the Teva role.<ref name="telegraph_stay">{{cite news |date=2017-07-14 |title=Pascal Soriot looks set to stay as AstraZeneca chief |url=https://www.telegraph.co.uk/business/2017/07/14/pascal-soriot-looks-set-stay-astrazeneca-chief/ |work=The Daily Telegraph |access-date=2026-02-24}}</ref>


=== COVID-19 Vaccine ===
=== COVID-19 Pandemic Response ===


One of the most prominent episodes of Soriot's tenure came during the COVID-19 pandemic, when AstraZeneca partnered with researchers at the University of Oxford to develop, manufacture, and distribute the Oxford–AstraZeneca COVID-19 vaccine. The vaccine became one of the most widely used globally, particularly in low- and middle-income countries, in part because of AstraZeneca's commitment to provide the vaccine on a not-for-profit basis during the pandemic. Soriot's role in leading the company through this unprecedented effort brought him significant public attention and was cited as a primary reason for his subsequent knighthood.<ref name="knighthood"/>
Soriot's leadership during the [[COVID-19 pandemic]] brought him to global prominence. AstraZeneca partnered with the University of Oxford to develop a COVID-19 vaccine, known as the Oxford–AstraZeneca vaccine (ChAdOx1 nCoV-19, marketed as Vaxzevria). The vaccine was one of the first to receive emergency authorisation worldwide and was distributed on a not-for-profit basis to low- and middle-income countries, a decision that distinguished AstraZeneca's approach from several of its competitors. Soriot's management of the vaccine's development, manufacturing scale-up, and global distribution was cited as a primary reason for his knighthood in the 2022 New Year Honours.<ref name="knighthood" /><ref name="gazette">{{cite web |title=New Year Honours 2022 – Supplement |url=https://www.thegazette.co.uk/London/issue/63714/supplement/B2 |publisher=The London Gazette |date=2022 |access-date=2026-02-24}}</ref>


The vaccine programme was not without controversy, including disputes with the European Union over delivery schedules and questions about the vaccine's efficacy and safety profile compared to mRNA-based alternatives. Nonetheless, the scale of the global rollout — with billions of doses supplied across numerous countries — was recognised as a substantial contribution to the pandemic response.
=== Revenue Growth and Strategic Ambitions (2025–2030) ===


=== Teva Pharmaceutical Approach ===
Under Soriot's continued leadership, AstraZeneca has set ambitious long-term revenue targets. In February 2026, Fierce Pharma reported that the company had set its sights on having more than 25 blockbuster drugs by 2030 to support a revenue ambition of $80 billion.<ref name="fierce_blockbusters">{{cite news |date=2026-02-10 |title=AstraZeneca sets sights on 25+ blockbusters by 2030 to fuel $80B revenue ambition |url=https://www.fiercepharma.com/pharma/astrazeneca-sets-sights-25-blockbusters-2030-fuel-80b-revenue-ambition |work=Fierce Pharma |access-date=2026-02-24}}</ref> Oncodaily reported that Soriot highlighted strong 2025 performance with continued growth, sharing results with investors and media.<ref name="oncodaily">{{cite news |date=2026-02-17 |title=Strong 2025 Performance, Pascal Soriot Highlights Continued Growth – AstraZeneca |url=https://oncodaily.com/voices/pascal-soriot-454750 |work=Oncodaily |access-date=2026-02-24}}</ref>


In 2017, reports emerged that Soriot had been approached to take the position of chief executive at [[Teva Pharmaceutical Industries]], the Israeli generic drug manufacturer. According to Israeli media reports, Soriot had initially agreed to take the role.<ref name="endpts_teva">{{cite news |last= |first= |date=2017 |title=Israeli newspaper reports that AstraZeneca CEO Pascal Soriot has agreed to take the helm at Teva |url=https://endpts.com/israeli-newspaper-reports-that-astrazeneca-ceo-pascal-soriot-has-agreed-to-take-the-helm-at-teva/ |work=Endpoints News |access-date=2026-02-24}}</ref><ref name="reuters_teva">{{cite news |last= |first= |date=2017 |title=AstraZeneca's Soriot and Teva |url=https://www.reuters.com/article/us-teva-pharm-ind-astrazeneca-ceo-idUSKBN19X2OB?il=0 |work=Reuters |access-date=2026-02-24}}</ref> However, Soriot ultimately decided to remain at AstraZeneca, a decision that was closely followed in the pharmaceutical industry and the financial press.<ref name="telegraph_stay">{{cite news |last= |first= |date=2017-07-14 |title=Pascal Soriot looks set to stay as AstraZeneca chief |url=https://www.telegraph.co.uk/business/2017/07/14/pascal-soriot-looks-set-stay-astrazeneca-chief/ |work=The Daily Telegraph |access-date=2026-02-24}}</ref> His decision to stay was interpreted as a reaffirmation of his commitment to AstraZeneca's long-term strategy and the transformation he had initiated.
=== US Investment and Drug Pricing ===


=== Views on Global Pharmaceutical Industry and Geopolitics ===
In the mid-2020s, Soriot increasingly focused AstraZeneca's investment on the United States market, which represented the company's largest source of revenue. In July 2025, Fortune reported that Soriot discussed his rationale for building more extensively in the US, stating that "Europe is losing ground" in terms of competitiveness for pharmaceutical investment.<ref name="fortune">{{cite news |date=2025-07-22 |title=AstraZeneca CEO Pascal Soriot on why he's building in the U.S.: 'Europe is losing ground' |url=https://fortune.com/2025/07/22/astrazeneca-ceo-pascal-soriot-building-us-europe/ |work=Fortune |access-date=2026-02-24}}</ref>


In the mid-2020s, Soriot became increasingly vocal about what he described as Europe's declining competitiveness in the global pharmaceutical industry. In a December 2025 interview with ''Le Monde'', he warned that "the pharmaceutical industry in Europe will be reduced to a shadow of itself within 15 years" without significant policy changes.<ref name="lemonde"/> He argued that the regulatory and pricing environments in Europe were making it increasingly difficult for pharmaceutical companies to compete with those based in the United States and China.
On the subject of drug pricing, Fierce Pharma reported in July 2025 that Soriot expressed support for a global "rebalancing of pricing" and indicated that AstraZeneca had been in extensive discussions with the US government, offering price reduction plans for its drugs.<ref name="fierce_pricing">{{cite news |date=2025-07-29 |title=AZ proposes US price cut options as CEO Pascal Soriot sides with global 'rebalancing of pricing' |url=https://www.fiercepharma.com/pharma/astrazeneca-ceo-soriot-sides-global-rebalancing-pricing-has-offered-us-price-reduction |work=Fierce Pharma |access-date=2026-02-24}}</ref> Bloomberg reported in November 2025 that Soriot had cultivated a deep relationship with the United States, including a willingness to engage with the administration of President [[Donald Trump]] on drug pricing negotiations.<ref name="bloomberg_profile" />


Speaking to ''Fortune'' in July 2025, Soriot explained his rationale for expanding AstraZeneca's presence in the United States, stating that "Europe is losing ground."<ref name="fortune">{{cite news |last= |first= |date=2025-07-22 |title=AstraZeneca CEO Pascal Soriot on why he's building in the U.S.: 'Europe is losing ground' |url=https://fortune.com/2025/07/22/astrazeneca-ceo-pascal-soriot-building-us-europe/ |work=Fortune |access-date=2026-02-24}}</ref> ''The Economist'' reported in August 2025 on Soriot's growing frustration with the business environment in Britain, describing him as "the pharma titan tiring of Britain."<ref name="economist">{{cite news |last= |first= |date=2025-08-08 |title=Pascal Soriot, the pharma titan tiring of Britain |url=https://www.economist.com/britain/2025/08/08/pascal-soriot-the-pharma-titan-tiring-of-britain |work=The Economist |access-date=2026-02-24}}</ref>
=== Advocacy for European Competitiveness ===


In a February 2026 interview with Semafor, Soriot addressed the broader geopolitical dynamics affecting the pharmaceutical industry, stating that Europe "cannot be naive" about its rivalry with the United States and China.<ref name="semafor">{{cite news |last= |first= |date=2026-02-20 |title=AstraZeneca's CEO on competing in the new world order |url=https://www.semafor.com/article/02/20/2026/astrazenecas-ceo-on-competing-in-the-new-world-order |work=Semafor |access-date=2026-02-24}}</ref>
By the mid-2020s, Soriot had become one of the most prominent voices in the pharmaceutical industry warning about the erosion of European competitiveness in life sciences. In an interview with Le Monde published in December 2025, he stated that "the pharmaceutical industry in Europe will be reduced to a shadow of itself within 15 years" unless the continent adopted more competitive policies for research, regulation, and investment.<ref name="lemonde" /> The Economist reported in August 2025 that Soriot, described as "a big believer in science," was growing frustrated with the regulatory and competitive environment in Britain.<ref name="economist">{{cite news |date=2025-08-08 |title=Pascal Soriot, the pharma titan tiring of Britain |url=https://www.economist.com/britain/2025/08/08/pascal-soriot-the-pharma-titan-tiring-of-britain |work=The Economist |access-date=2026-02-24}}</ref>


On the subject of drug pricing in the United States, Soriot expressed willingness to work with the U.S. government under the Trump administration. In July 2025, it was reported that AstraZeneca had proposed price reduction plans for its drugs in the U.S. as part of what Soriot described as a global "rebalancing of pricing."<ref name="fierce_pricing">{{cite news |last= |first= |date=2025-07-29 |title=AZ proposes US price cut options as CEO Pascal Soriot sides with global 'rebalancing of pricing' |url=https://www.fiercepharma.com/pharma/astrazeneca-ceo-soriot-sides-global-rebalancing-pricing-has-offered-us-price-reduction |work=Fierce Pharma |access-date=2026-02-24}}</ref> Bloomberg reported in November 2025 that Soriot was "willing to compromise" in his dealings with the Trump administration on drug pricing issues.<ref name="bloomberg_2025"/>
In February 2026, Semafor reported on an interview in which Soriot stated that Europe "cannot be naive" about its rivalry with the US and China, underscoring his view that global pharmaceutical competition required more strategic thinking from European policymakers.<ref name="semafor">{{cite news |date=2026-02-20 |title=AstraZeneca's CEO on competing in the new world order |url=https://www.semafor.com/article/02/20/2026/astrazenecas-ceo-on-competing-in-the-new-world-order |work=Semafor |access-date=2026-02-24}}</ref>


== Personal Life ==
== Personal Life ==


Soriot holds dual French and Australian nationality. He has two children.<ref name="roche_cv"/> Despite leading a British-Swedish company headquartered in Cambridge, England, Soriot has maintained strong connections to Australia, where he resided for a period of his career. Details of his private life have remained largely out of the public domain, with Soriot preferring to keep personal matters separate from his public role as a corporate leader.
Soriot holds both French and Australian citizenship.<ref name="lemonde" /> He has two children.<ref name="knighthood" /> He has maintained a relatively private personal life compared to his public profile as a corporate executive. His dual nationality has been frequently noted in media coverage, particularly in the context of his leadership of a British-Swedish company while holding non-British citizenship.


== Recognition ==
== Recognition ==


In the 2022 New Year Honours, Soriot was awarded a [[Knight Bachelor|knighthood]] by the British Crown, entitling him to use the style "Sir." The honour was conferred for his services to the UK life sciences sector and his leadership of the global response to the COVID-19 pandemic, particularly AstraZeneca's role in developing and distributing the Oxford–AstraZeneca vaccine.<ref name="knighthood"/> The award was published in ''[[The London Gazette]]''.<ref>{{cite web |title=New Year Honours 2022 |url=https://www.thegazette.co.uk/London/issue/63714/supplement/B2 |publisher=The London Gazette |access-date=2026-02-24}}</ref>
In the 2022 New Year Honours, Soriot was awarded a [[Knight Bachelor|Knight Bachelor]] by the British Crown for his services to the United Kingdom's life sciences industry and for his leadership of the global response to the COVID-19 pandemic. The honour was published in ''The London Gazette''.<ref name="gazette" /> AstraZeneca issued a press release confirming the knighthood, noting Soriot's role in the development and global distribution of the Oxford–AstraZeneca COVID-19 vaccine.<ref name="knighthood" />


Throughout his career, Soriot has been the subject of extensive coverage in the financial and business press. His leadership of AstraZeneca has been profiled in publications including ''The Financial Times'',<ref>{{cite news |last= |first= |date=2016-01 |title=AstraZeneca profile |url=https://www.ft.com/content/39020eb0-b627-11e5-b147-e5e5bba42e51 |work=Financial Times |access-date=2026-02-24}}</ref> ''Bloomberg'', ''The Economist'', ''The New York Times'', ''The Guardian'', ''Le Monde'', and ''Fortune'', among others. His management of AstraZeneca's defence against the 2014 Pfizer bid and the subsequent transformation of the company have been cited as among the most significant corporate turnarounds in the European pharmaceutical industry in the 2010s and 2020s.
Under Soriot's leadership, AstraZeneca's market capitalisation and revenue have grown substantially since 2012. His role in defending the company against the 2014 Pfizer bid and subsequently delivering on his promises regarding the pipeline's potential has been a recurring theme in financial media coverage.<ref name="standard" /> Bloomberg, The Economist, Fortune, and Le Monde have all profiled Soriot as one of the most influential figures in the global pharmaceutical industry.<ref name="bloomberg_profile" /><ref name="economist" /><ref name="fortune" /><ref name="lemonde" />


== Legacy ==
== Legacy ==


Soriot's tenure at AstraZeneca, which by 2026 had extended beyond thirteen years, has been marked by a sustained effort to reposition the company from one facing significant revenue challenges into a major force in oncology and other therapeutic areas. The company's ambition to achieve more than 25 blockbuster products and $80 billion in revenue by 2030 reflects the scale of the transformation undertaken under his leadership.<ref name="fierce_2026"/>
Soriot's tenure at AstraZeneca, which began in 2012 and continues as of 2026, represents one of the longer and more consequential periods of leadership at a major pharmaceutical company. He took charge of a company that was losing patent protection on several of its most important products and facing questions about its long-term viability as an independent entity. His decision to invest heavily in oncology research and to defend the company's independence during the 2014 Pfizer bid proved pivotal, as the company's subsequent pipeline development generated substantial returns for shareholders.


His role in the COVID-19 vaccine programme brought AstraZeneca and its chief executive to a level of public recognition unusual for pharmaceutical industry leaders. The decision to supply the Oxford–AstraZeneca vaccine on a not-for-profit basis during the acute phase of the pandemic, with billions of doses distributed globally, was one of the largest public health interventions led by a single private-sector entity.
The COVID-19 pandemic placed Soriot in a position of global public visibility. AstraZeneca's decision to distribute the Oxford–AstraZeneca vaccine on a not-for-profit basis to developing nations was noted as a significant contribution to global public health, and Soriot's leadership during this period was recognised with his British knighthood.<ref name="knighthood" />


Soriot's increasingly public commentary on European competitiveness in the pharmaceutical sector has contributed to broader policy debates about the future of the life sciences industry on the continent. His warnings about the risk of Europe falling behind the United States and China have been cited in discussions about regulatory reform, pricing policy, and industrial strategy in the European Union and the United Kingdom.<ref name="lemonde"/><ref name="economist"/><ref name="semafor"/>
His advocacy for European pharmaceutical competitiveness in the 2020s has positioned him as a prominent voice in policy debates about industrial strategy, research funding, and regulatory reform across Europe. His warnings about the decline of the European pharmaceutical industry relative to the US and China have been cited across major international publications.<ref name="lemonde" /><ref name="economist" /><ref name="fortune" /><ref name="semafor" />


As of early 2026, Soriot continues to serve as CEO of AstraZeneca, leading the company through a period of expansion and navigating a complex geopolitical landscape that includes trade tensions, evolving drug pricing policies, and intensifying competition in the global biopharmaceutical market.
As of early 2026, AstraZeneca under Soriot's leadership was pursuing a target of more than 25 blockbuster drugs by 2030 and an $80 billion revenue ambition, figures that, if achieved, would represent a fundamental transformation from the company he inherited in 2012.<ref name="fierce_blockbusters" />


== References ==
== References ==
Line 98: Line 101:
[[Category:1959 births]]
[[Category:1959 births]]
[[Category:Living people]]
[[Category:Living people]]
[[Category:Australian businesspeople]]
[[Category:French businesspeople]]
[[Category:French businesspeople]]
[[Category:Australian businesspeople]]
[[Category:Knights Bachelor]]
[[Category:AstraZeneca people]]
[[Category:AstraZeneca people]]
[[Category:Roche people]]
[[Category:Roche people]]
[[Category:Knights Bachelor]]
[[Category:HEC Paris alumni]]
[[Category:HEC Paris alumni]]
[[Category:French chief executives]]
[[Category:Chief executive officers]]
[[Category:Pharmaceutical industry people]]
[[Category:Pharmaceutical industry people]]
[[Category:French emigrants to Australia]]
<html><script type="application/ld+json">
<html><script type="application/ld+json">
{
{

Latest revision as of 05:16, 24 February 2026



Pascal Soriot
BornPascal Claude Roland Soriot
23 5, 1959
BirthplaceFrance
NationalityFrench, Australian
OccupationBusinessman
TitleCEO, AstraZeneca
EducationÉcole nationale vétérinaire d'Alfort
HEC Paris
Children2

Sir Pascal Claude Roland Soriot (born 23 May 1959) is a French-born Australian businessman who has served as chief executive officer of AstraZeneca, the British-Swedish multinational pharmaceutical and biotechnology company, since 2012. Appointed at a time when the company faced expiring patents on key drugs and a thinning development pipeline, Soriot oversaw a strategic transformation that repositioned AstraZeneca as a major force in oncology and other therapeutic areas. His tenure has been marked by large-scale investment in research and development, significant revenue growth, and a prominent role during the COVID-19 pandemic, when AstraZeneca partnered with the University of Oxford to develop and distribute one of the world's most widely used vaccines. Before joining AstraZeneca, Soriot held senior positions at Roche and spent more than two decades at various pharmaceutical firms. He was awarded a British knighthood in the 2022 New Year Honours for services to the United Kingdom's life sciences sector and for his leadership during the global response to the COVID-19 pandemic.[1] In recent years, Soriot has been an outspoken advocate for European competitiveness in the pharmaceutical sector, warning that the continent risks falling behind the United States and China in life sciences innovation.[2]

Early Life

Pascal Claude Roland Soriot was born on 23 May 1959 in France. Details regarding his family background and upbringing have not been extensively documented in public sources. He later obtained Australian citizenship, and is frequently described in corporate and media profiles as French-born Australian.[2][3]

Education

Soriot studied at the École nationale vétérinaire d'Alfort, one of France's leading veterinary schools, where he received training in veterinary science. He subsequently attended HEC Paris, the prestigious French business school, where he completed a programme in business administration.[4] This combination of scientific and business education formed the foundation for his career in the pharmaceutical industry.

Career

Early Career and Pharmaceutical Industry Beginnings

Soriot began his professional career in the pharmaceutical sector in 1982.[4] Over the following decades, he held positions at several major pharmaceutical companies. His early career included roles at firms operating across the global pharmaceutical landscape, during which he gained experience in commercial operations and general management across multiple geographic markets.

Roche

Before joining AstraZeneca, Soriot served as chief operating officer of the pharmaceuticals division at Roche, the Swiss multinational healthcare company.[5] At Roche, he was a member of the corporate executive committee and was responsible for overseeing the company's global pharmaceutical commercial operations. His tenure at Roche established his reputation as a senior pharmaceutical industry executive with deep expertise in drug commercialisation and operations management.[6][7]

Appointment as AstraZeneca CEO

On 28 August 2012, AstraZeneca announced that Soriot would become its new chief executive officer, succeeding David Brennan.[8] The appointment was widely reported in the financial press, as AstraZeneca was at the time facing substantial challenges. The company's portfolio included several blockbuster drugs that were nearing the end of their patent protection, raising concerns about future revenue declines. Its research and development pipeline was considered thin relative to its peers, and investor confidence had waned.[9][3]

The Daily Telegraph reported that Soriot's background at Roche, where he had overseen the commercial operations of some of the industry's leading cancer drugs, made him a strong candidate to lead AstraZeneca's turnaround.[10]

Transformation of AstraZeneca

Upon taking charge, Soriot embarked on a strategy centred on rebuilding the company's drug development pipeline through a combination of internal research investment and external acquisitions and partnerships. He placed a particular strategic emphasis on oncology, which became the cornerstone of AstraZeneca's growth strategy under his leadership. The company invested heavily in cancer treatment research and built a portfolio of oncology drugs that became a significant driver of revenue growth.[11]

Bloomberg described Soriot as having turned AstraZeneca into "an oncology powerhouse" characterised by "a high-pressure culture and a deep relationship with the US."[11] Le Monde noted in December 2025 that since taking over in 2012, Soriot had "transformed the British pharmaceutical company that once lagged" behind its competitors.[2]

Pfizer Takeover Bid (2014)

In 2014, AstraZeneca became the target of a major takeover bid from the American pharmaceutical company Pfizer. The Evening Standard reported on the bid battle, describing it as approximately £63 billion in value and quoting Soriot's defence of the company's independent strategy. Soriot argued that AstraZeneca could deliver greater value to shareholders by continuing to develop its pipeline as a standalone company rather than being absorbed into Pfizer.[12] Pfizer's bid was ultimately unsuccessful, and AstraZeneca remained independent. The episode was considered a defining moment of Soriot's tenure, as the company's subsequent performance under his leadership vindicated his argument that AstraZeneca's pipeline would generate substantial value over time.

Teva Pharmaceutical Approach (2017)

In July 2017, reports emerged that Soriot had been approached to become the chief executive of Teva Pharmaceutical Industries, the Israeli generic drug manufacturer. An Israeli newspaper reported that Soriot had agreed to take the position, prompting speculation about his potential departure from AstraZeneca.[13] Reuters also reported on the possibility of Soriot moving to Teva.[14] However, the Daily Telegraph subsequently reported that Soriot appeared set to remain at AstraZeneca, and he ultimately did not take the Teva role.[15]

COVID-19 Pandemic Response

Soriot's leadership during the COVID-19 pandemic brought him to global prominence. AstraZeneca partnered with the University of Oxford to develop a COVID-19 vaccine, known as the Oxford–AstraZeneca vaccine (ChAdOx1 nCoV-19, marketed as Vaxzevria). The vaccine was one of the first to receive emergency authorisation worldwide and was distributed on a not-for-profit basis to low- and middle-income countries, a decision that distinguished AstraZeneca's approach from several of its competitors. Soriot's management of the vaccine's development, manufacturing scale-up, and global distribution was cited as a primary reason for his knighthood in the 2022 New Year Honours.[1][16]

Revenue Growth and Strategic Ambitions (2025–2030)

Under Soriot's continued leadership, AstraZeneca has set ambitious long-term revenue targets. In February 2026, Fierce Pharma reported that the company had set its sights on having more than 25 blockbuster drugs by 2030 to support a revenue ambition of $80 billion.[17] Oncodaily reported that Soriot highlighted strong 2025 performance with continued growth, sharing results with investors and media.[18]

US Investment and Drug Pricing

In the mid-2020s, Soriot increasingly focused AstraZeneca's investment on the United States market, which represented the company's largest source of revenue. In July 2025, Fortune reported that Soriot discussed his rationale for building more extensively in the US, stating that "Europe is losing ground" in terms of competitiveness for pharmaceutical investment.[19]

On the subject of drug pricing, Fierce Pharma reported in July 2025 that Soriot expressed support for a global "rebalancing of pricing" and indicated that AstraZeneca had been in extensive discussions with the US government, offering price reduction plans for its drugs.[20] Bloomberg reported in November 2025 that Soriot had cultivated a deep relationship with the United States, including a willingness to engage with the administration of President Donald Trump on drug pricing negotiations.[11]

Advocacy for European Competitiveness

By the mid-2020s, Soriot had become one of the most prominent voices in the pharmaceutical industry warning about the erosion of European competitiveness in life sciences. In an interview with Le Monde published in December 2025, he stated that "the pharmaceutical industry in Europe will be reduced to a shadow of itself within 15 years" unless the continent adopted more competitive policies for research, regulation, and investment.[2] The Economist reported in August 2025 that Soriot, described as "a big believer in science," was growing frustrated with the regulatory and competitive environment in Britain.[21]

In February 2026, Semafor reported on an interview in which Soriot stated that Europe "cannot be naive" about its rivalry with the US and China, underscoring his view that global pharmaceutical competition required more strategic thinking from European policymakers.[22]

Personal Life

Soriot holds both French and Australian citizenship.[2] He has two children.[1] He has maintained a relatively private personal life compared to his public profile as a corporate executive. His dual nationality has been frequently noted in media coverage, particularly in the context of his leadership of a British-Swedish company while holding non-British citizenship.

Recognition

In the 2022 New Year Honours, Soriot was awarded a Knight Bachelor by the British Crown for his services to the United Kingdom's life sciences industry and for his leadership of the global response to the COVID-19 pandemic. The honour was published in The London Gazette.[16] AstraZeneca issued a press release confirming the knighthood, noting Soriot's role in the development and global distribution of the Oxford–AstraZeneca COVID-19 vaccine.[1]

Under Soriot's leadership, AstraZeneca's market capitalisation and revenue have grown substantially since 2012. His role in defending the company against the 2014 Pfizer bid and subsequently delivering on his promises regarding the pipeline's potential has been a recurring theme in financial media coverage.[12] Bloomberg, The Economist, Fortune, and Le Monde have all profiled Soriot as one of the most influential figures in the global pharmaceutical industry.[11][21][19][2]

Legacy

Soriot's tenure at AstraZeneca, which began in 2012 and continues as of 2026, represents one of the longer and more consequential periods of leadership at a major pharmaceutical company. He took charge of a company that was losing patent protection on several of its most important products and facing questions about its long-term viability as an independent entity. His decision to invest heavily in oncology research and to defend the company's independence during the 2014 Pfizer bid proved pivotal, as the company's subsequent pipeline development generated substantial returns for shareholders.

The COVID-19 pandemic placed Soriot in a position of global public visibility. AstraZeneca's decision to distribute the Oxford–AstraZeneca vaccine on a not-for-profit basis to developing nations was noted as a significant contribution to global public health, and Soriot's leadership during this period was recognised with his British knighthood.[1]

His advocacy for European pharmaceutical competitiveness in the 2020s has positioned him as a prominent voice in policy debates about industrial strategy, research funding, and regulatory reform across Europe. His warnings about the decline of the European pharmaceutical industry relative to the US and China have been cited across major international publications.[2][21][19][22]

As of early 2026, AstraZeneca under Soriot's leadership was pursuing a target of more than 25 blockbuster drugs by 2030 and an $80 billion revenue ambition, figures that, if achieved, would represent a fundamental transformation from the company he inherited in 2012.[17]

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 "AstraZeneca's Pascal Soriot awarded British Knighthood for services to UK life sciences and leadership of global response to the COVID pandemic".AstraZeneca.2022.https://www.astrazeneca.com/media-centre/press-releases/2022/astrazenecas-pascal-soriot-awarded-british-knighthood-services-uk-life-sciences-leadership-global-response-covid-pandemic.html.Retrieved 2026-02-24.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 "AstraZeneca CEO Pascal Soriot: 'The pharmaceutical industry in Europe will be reduced to a shadow of itself within 15 years'".Le Monde.2025-12-18.https://www.lemonde.fr/en/economy/article/2025/12/18/astrazeneca-ceo-pascal-soriot-the-pharmaceutical-industry-in-europe-will-be-reduced-to-a-shadow-of-itself-within-15-years_6748620_19.html.Retrieved 2026-02-24.
  3. ↑ 3.0 3.1 "AstraZeneca names new chief executive Pascal Soriot".The Guardian.2012-08-28.https://www.theguardian.com/business/2012/aug/28/astrazeneca-new-chief-executive-pascal-soriot.Retrieved 2026-02-24.
  4. ↑ 4.0 4.1 "CV Pascal Soriot".Roche.http://www.roche.com/cv_soriot.pdf.Retrieved 2026-02-24.
  5. ↑ "Executive Committee – Pascal Soriot".Roche.http://www.roche.com/about_roche/management/executive_committee/executive_commitee-pascal-soriot.htm.Retrieved 2026-02-24.
  6. ↑ "Pascal Soriot – Executive Profile".Bloomberg.https://www.bloomberg.com/research/stocks/people/person.asp?personId=11538206&ticker=RO:SW.Retrieved 2026-02-24.
  7. ↑ "Pascal Soriot – Former Executive Committee Member".Roche.https://www.roche.com/about/governance/ec-bod-former/pascal-soriot.Retrieved 2026-02-24.
  8. ↑ "AstraZeneca Names Roche's Pascal Soriot as CEO".Bloomberg.2012-08-28.https://www.bloomberg.com/news/2012-08-28/astrazeneca-names-roche-s-pascal-soriot-as-ceo.html.Retrieved 2026-02-24.
  9. ↑ "AstraZeneca's Next C.E.O. Is Pascal Soriot of Roche".The New York Times.2012-08-29.https://www.nytimes.com/2012/08/29/business/astrazenecas-next-ceo-is-pascal-soriot-of-roche.html.Retrieved 2026-02-24.
  10. ↑ "AstraZeneca appoints Roche's Pascal Soriot as new chief".The Daily Telegraph.2012-08-28.https://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/9504462/AstraZeneca-appoints-Roches-Pascal-Soriot-as-new-chief.html.Retrieved 2026-02-24.
  11. ↑ 11.0 11.1 11.2 11.3 "AstraZeneca's CEO Is Willing to Compromise — When It's for Trump".Bloomberg.2025-11-05.https://www.bloomberg.com/news/features/2025-11-05/astrazeneca-ceo-pascal-soriot-on-the-trump-drug-price-deal-and-company-culture.Retrieved 2026-02-24.
  12. ↑ 12.0 12.1 "AstraZeneca chief Pascal Soriot: I can carry on curing the company, says scientist in £63bn bid battle".Evening Standard.2014.https://www.standard.co.uk/business/markets/astrazeneca-chief-pascal-soriot-i-can-carry-on-curing-the-company-says-scientist-in-63bn-bid-battle-9383150.html.Retrieved 2026-02-24.
  13. ↑ "Israeli newspaper reports that AstraZeneca CEO Pascal Soriot has agreed to take the helm at Teva".Endpoints News.2017.https://endpts.com/israeli-newspaper-reports-that-astrazeneca-ceo-pascal-soriot-has-agreed-to-take-the-helm-at-teva/.Retrieved 2026-02-24.
  14. ↑ "Teva – AstraZeneca CEO".Reuters.2017.https://www.reuters.com/article/us-teva-pharm-ind-astrazeneca-ceo-idUSKBN19X2OB?il=0.Retrieved 2026-02-24.
  15. ↑ "Pascal Soriot looks set to stay as AstraZeneca chief".The Daily Telegraph.2017-07-14.https://www.telegraph.co.uk/business/2017/07/14/pascal-soriot-looks-set-stay-astrazeneca-chief/.Retrieved 2026-02-24.
  16. ↑ 16.0 16.1 "New Year Honours 2022 – Supplement".The London Gazette.2022.https://www.thegazette.co.uk/London/issue/63714/supplement/B2.Retrieved 2026-02-24.
  17. ↑ 17.0 17.1 "AstraZeneca sets sights on 25+ blockbusters by 2030 to fuel $80B revenue ambition".Fierce Pharma.2026-02-10.https://www.fiercepharma.com/pharma/astrazeneca-sets-sights-25-blockbusters-2030-fuel-80b-revenue-ambition.Retrieved 2026-02-24.
  18. ↑ "Strong 2025 Performance, Pascal Soriot Highlights Continued Growth – AstraZeneca".Oncodaily.2026-02-17.https://oncodaily.com/voices/pascal-soriot-454750.Retrieved 2026-02-24.
  19. ↑ 19.0 19.1 19.2 "AstraZeneca CEO Pascal Soriot on why he's building in the U.S.: 'Europe is losing ground'".Fortune.2025-07-22.https://fortune.com/2025/07/22/astrazeneca-ceo-pascal-soriot-building-us-europe/.Retrieved 2026-02-24.
  20. ↑ "AZ proposes US price cut options as CEO Pascal Soriot sides with global 'rebalancing of pricing'".Fierce Pharma.2025-07-29.https://www.fiercepharma.com/pharma/astrazeneca-ceo-soriot-sides-global-rebalancing-pricing-has-offered-us-price-reduction.Retrieved 2026-02-24.
  21. ↑ 21.0 21.1 21.2 "Pascal Soriot, the pharma titan tiring of Britain".The Economist.2025-08-08.https://www.economist.com/britain/2025/08/08/pascal-soriot-the-pharma-titan-tiring-of-britain.Retrieved 2026-02-24.
  22. ↑ 22.0 22.1 "AstraZeneca's CEO on competing in the new world order".Semafor.2026-02-20.https://www.semafor.com/article/02/20/2026/astrazenecas-ceo-on-competing-in-the-new-world-order.Retrieved 2026-02-24.

Retrieved from "https://biography.wiki/index.php?title=Pascal_Soriot&oldid=477"